Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Polynovo Limited (OtherCALZF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGXResearch Report) and Polynovo Limited (CALZFResearch Report) with bullish sentiments.

Protagonist Therapeutics (PTGX)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $21.00. The company’s shares closed last Wednesday at $7.65, close to its 52-week low of $6.91.

According to, Wolleben has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.2% and a 19.6% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.75.

See today’s best-performing stocks on TipRanks >>

Polynovo Limited (CALZF)

Bell Potter analyst John Hester maintained a Buy rating on Polynovo Limited on December 2 and set a price target of A$2.30. The company’s shares closed last Monday at $1.40, close to its 52-week high of $1.50.

According to, Hester is a 4-star analyst with an average return of 13.3% and a 81.8% success rate. Hester covers the Healthcare sector, focusing on stocks such as Paradigm Biopharmaceuticals Ltd., Telix Pharmaceuticals Ltd., and Nanosonics Limited.

Currently, the analyst consensus on Polynovo Limited is a Moderate Buy with an average price target of $1.21.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PTGX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More